The treatment of cognitive impairment in schizophrenia

Donald C. Goff, Michele Hill, Deanna Barch

Research output: Contribution to journalArticlepeer-review

134 Scopus citations


Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic targets have been identified for cognitive enhancing agents, including receptors involved in dopaminergic, glutamatergic, GABAergic, serotonergic and cholinergic neurotransmission. In addition, new approaches to drug development have been directed towards neuroprotection and the facilitation of neuroplasticity. While several pharmacologic agents and cognitive remediation have shown promise in early trials, no treatment has yet demonstrated efficacy in large replication trials. The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research.

Original languageEnglish
Pages (from-to)245-253
Number of pages9
JournalPharmacology Biochemistry and Behavior
Issue number2
StatePublished - Aug 2011


  • Clinical trials
  • Cognition
  • Drug development
  • Pharmacology
  • Schizophrenia


Dive into the research topics of 'The treatment of cognitive impairment in schizophrenia'. Together they form a unique fingerprint.

Cite this